Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Condition Directory

Lymphoma clinical trials

Directory of U.S. ClinicalTrials.gov public records for Lymphoma. Browse Lymphoma recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 28, 2026 Report an issue

ClinicalTrials.gov public records Last synced Oct 27, 2026, 10:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
5757
Shown on this page
12
Current sort
Recently updated
Condition scope
Lymphoma
Additional filters apply within this condition.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

How Lymphoma studies are organized in the registry

Lymphoma records divide between Hodgkin and non-Hodgkin disease, and non-Hodgkin studies usually name the histology directly — diffuse large B-cell (DLBCL), follicular, mantle cell, and others. Subtype abbreviations are the most reliable narrowing terms because they appear in titles and condition fields verbatim.

Terms that often appear in related listings
DLBCL follicular lymphoma mantle cell Hodgkin

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Filter and sort this condition

These controls apply only within Lymphoma. Default order is Recently updated. Add location, sponsor, treatment, or recruitment status to narrow this condition page further.

Reset condition filters
Clear filters
Showing 397–408 of 5,757 matching trials for Lymphoma.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Active, not recruiting Phase 3 Interventional Results available

A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

NCT03462719
View directory record Official record
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
Interventions
Ibrutinib, Venetoclax, Chlorambucil, Obinutuzumab, Ibrutinib (as Subsequent Therapy)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
3
States / cities
Louisville, Kentucky • Hackensack, New Jersey • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 27, 2026, 10:37 PM EDT
Active, not recruiting No phase listed Observational

A Non-interventional, International, Multicentre Clinical Research Study to Build the Largest Collection of Multimodal Data (Including Clinical Data, Imaging Data and Omics Data) in Oncology

NCT06625203
View directory record Official record
Conditions
Diffuse Large B Cell Lymphoma, Solid Tumor Cancer
Interventions
Not listed
Lead sponsor
OWKIN
Other
Eligibility
18 Years and older
Enrollment
7,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 27, 2026, 10:37 PM EDT
Recruiting Phase 2 Interventional

A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)

NCT06514794
View directory record Official record
Conditions
T-cell Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Interventions
WU-CART-007
Biological
Lead sponsor
Allotera Therapeutics
Industry
Eligibility
6 Months and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
16
States / cities
Duarte, California • Los Angeles, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 27, 2026, 10:37 PM EDT
Recruiting Not applicable Interventional

Increasing Resiliency Among Early Post-Treatment Lymphoma Survivors

NCT07014293
View directory record Official record
Conditions
Lymphoma
Interventions
Enhanced Usual Care, SMART3RP-Lymphoma
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 27, 2026, 10:37 PM EDT
Recruiting Phase 3 Interventional

A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

NCT06742996
View directory record Official record
Conditions
Mantle Cell Lymphoma, B Cell Lymphoma
Interventions
Sonrotoclax, Zanubrutinib, Placebo
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
41
States / cities
Birmingham, Alabama • Tucson, Arizona • Fresno, California + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 27, 2026, 10:37 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma

NCT07439653
View directory record Official record
Conditions
Histologically Confirmed Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Interventions
TORL-5-700, TORL-5-700 at MTD/RP2D, TORL-5-700 at MTD/RP2D in combination with another agent
Drug
Lead sponsor
TORL Biotherapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
9
States / cities
Fullerton, California • Los Alamitos, California • Santa Monica, California + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 27, 2026, 10:37 PM EDT
Active, not recruiting Phase 1 Interventional

A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

NCT05424822
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
Interventions
JNJ-80948543
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
Duarte, California • New York, New York • Nashville, Tennessee + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 27, 2026, 10:37 PM EDT
Suspended Phase 1 Interventional

Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome

NCT03494569
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia, Acute Myeloid Leukemia in Remission, Hematopoietic Cell Transplantation Recipient, Minimal Residual Disease, Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia
Interventions
Fludarabine, Laboratory Biomarker Analysis, Melphalan, Total Marrow Irradiation
Drug · Other · Radiation
Lead sponsor
City of Hope Medical Center
Other
Eligibility
12 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 27, 2026, 10:37 PM EDT
Recruiting Phase 2 Interventional

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

NCT03418038
View directory record Official record
Conditions
Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Hodgkin Lymphoma, Recurrent Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Lymphoma, Chronic Myelomonocytic Leukemia
Interventions
Ascorbic Acid, Carboplatin, Cisplatin, Cytarabine, Dexamethasone, Etoposide, Gemcitabine Hydrochloride, Ifosfamide, Laboratory Biomarker Analysis, Oxaliplatin, Placebo Administration, Questionnaire Administration, Rituximab, Decitabine, Biospecimen Collection, Core Biopsy, Bone Marrow Aspiration, Bone Marrow Biopsy, Echocardiography, Positron Emission Tomography, Magnetic Resonance Imaging, Central Venous Cannula Insertion, Portacath Placement, Computed Tomography, Decitabine and Cedazuridine
Dietary Supplement · Drug · Other + 2 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2033
U.S. locations
4
States / cities
Mankato, Minnesota • Rochester, Minnesota • Eau Claire, Wisconsin + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 27, 2026, 10:37 PM EDT
Enrolling by invitation Not applicable Interventional

TRTME: Improving Outpatient Initiation of Medication for Opioid Use Disorder Following Hospitalization

NCT07780097
View directory record Official record
Conditions
Opioid Use Disorder, Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe
Interventions
TRTME
Behavioral
Lead sponsor
T. John Winhusen, PhD
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 27, 2026, 10:37 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers Results available

CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant

NCT03560752
View directory record Official record
Conditions
Accelerated Phase CML, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Chronic Lymphocytic Leukemia, Chronic Phase CML, BCR-ABL1 Positive, Cytomegalovirus Positive, Donor, Hematopoietic Cell Transplant Recipient, Hodgkin Lymphoma, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma, Myelofibrosis, Hematopoietic and Lymphoid Cell Neoplasm
Interventions
Multi-peptide CMV-Modified Vaccinia Ankara Vaccine
Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 27, 2026, 10:37 PM EDT
Active, not recruiting Phase 2 Interventional

Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma

NCT05600686
View directory record Official record
Conditions
Double-Expressor Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
Interventions
Cyclophosphamide, Doxorubicin, Etoposide, Loncastuximab Tesirine, Prednisone, Rituximab, Vincristine
Drug · Biological
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Sacramento, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 27, 2026, 10:37 PM EDT

About this Lymphoma clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Lymphoma as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results
Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Lymphoma.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Lymphoma.